SHORT DURATION VERSUS 1-YEAR DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTS IMPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS  by Spinetto, Pedro Villablanca et al.
A109
JACC March 17, 2015
Volume 65, Issue 10S
Acute Coronary Syndromes
shoRt duRation veRsus 1-yeaR dual antiplatelet theRapy aFteR dRug-eluting stents 
implantation: systematic Review and meta-analysis oF Randomized contRolled 
tRials
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 3:45 p.m.-4:30 p.m.
Session Title: ACS: Procedural and Long-Term Antithrombotic Therapy
Abstract Category: 3. Acute Coronary Syndromes: Therapy
Presentation Number: 1139-088
Authors: Pedro Villablanca Spinetto, David Briceno, Amell Fredrik, Felipe Albuquerque, Salvador Villablanca, Mark Menegus, Vankeepuram 
Srinivas, Mark Greenberg, Anna Bortnick, Ernest Monrad, Michael Johnson, Robert Pyo, Montefiore Medical Center/Albert Einstein College 
of Medicine, New York, NY, USA, Universidad de Valparaiso, Valparaiso, Chile
background: The benefits of 1-year of dual antiplatelet therapy (DAPT) as compared with short-term (≤ 6 months), in patients undergoing 
percutaneous coronary intervention (PCI) after drug-eluting stents (DES) remains controversial. We performed a meta-analysis of 1-year 
versus short-term duration DAPT in patients undergoing PCI with DES.
methods:  We conducted an electronic database search of randomized controlled trials (RCT). Efficacy endpoints included cardiac 
mortality, all-cause mortality, myocardial infarction (MI), stroke, and stent thrombosis. Safety endpoints included major bleeding, all 
bleeding, target vessel revascularization (TVR). Odds ratios (OR) and 95% confidence intervals (CI) were computed using the Mantel-
Haenszel (MH) method. Fixed-effect model was used; if heterogeneity (I2)>40, effects were obtained with a random model.
Results:  Five RCT were included and yielded 9.556 patients. There was no significant difference for all measured efficacy endpoints 
(Figure). We found a significant benefit favoring short-term DAPT for major bleeding (OR 0.5 [95% CI 0.3-0.82], p =0.006) and all bleeding 
(OR 0.63 [95% CI 0.46-0.87], p =0.005). No heterogeneity was seen. Exclusion of any single study from the analysis did not alter the 
overall result of our analysis.
conclusion:  This meta-analysis showed no benefit of 1-year versus short-term therapy in patients undergoing PCI with DES. However, 
there is a significant harm with respect bleeding associated with 1-year therapy of DAPT.
 
